RxDoctor Payments Data

Alok Shukla, MD

Internal Medicine · Roseville, MINPI 1508948183

Payments from drug & device makers

$456in general payments, 2019–2025

Across 26 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$72
  • AstraZeneca$66
  • Novo Nordisk$65
  • Lilly USA, LLC$40
  • Preventice Services, LLC$37
  • Pacira Pharmaceuticals Incorporated$27
  • plus $148 from 8 others

What the payments were for

  • Food & beverage$456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$456 in reported general payments places this provider in the 60th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$210,327
Medicare patients
215
Services billed
3,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide235$270,887
OzempicSemaglutide204$229,026
EliquisApixaban135$115,756
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$85,809
CreonLipase/Protease/Amylase20$71,258
LinzessLinaclotide54$42,805
RybelsusSemaglutide27$41,654
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl216$38,929
Tresiba Flextouch U-200Insulin Degludec23$21,353
TrulicityDulaglutide18$20,024
ZubsolvBuprenorphine Hcl/Naloxone Hcl26$15,153
XareltoRivaroxaban17$14,782
TradjentaLinagliptin24$12,396
SuboxoneBuprenorphine Hcl/Naloxone Hcl22$10,966
Breo ElliptaFluticasone/Vilanterol23$10,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$40$290,911253 claims
Novo NordiskOzempic, Rybelsus$65$270,680231 claims
PfizerEliquis$13$115,756135 claims
GSKTrelegy Ellipta, Breo Ellipta$26$96,264141 claims
Johnson & JohnsonXarelto$15$14,78217 claims
Indivior Inc.Suboxone$21$10,96622 claims
AstraZenecaFarxiga$66$7,38112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →